To discuss the future therapeutic landscape of the adjuvant setting, with a special focus on the Italian scenario, a panel of Italian clinicians, experts in the clinical management of HR+ HER2− breast cancer, gathered for a roundtable meeting. This evidence concerns the gene ERBB2 and breast cancer.